腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02137 腾盛博药-B

休市中 09-04 16:08:01

0.930

+0.020

+2.20%

最高0.940	最低0.900	成交量30.35万
今开0.925	昨收0.910	日振幅4.40%
总市值6.71亿	流通市值6.71亿	总股本7.22亿
成交额28.03万	换手率0.04%	流通股本7.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02137","market":"HK","secType":"STK","nameCN":"腾盛博药-B","latestPrice":0.93,"timestamp":1788509281932,"preClose":0.91,"halted":0,"volume":303500,"delay":0,"changeRate":0.021978021978021997,"floatShares":722000000,"shares":722000000,"eps":-0.36049536876029165,"marketStatus":"休市中","change":0.02,"latestTime":"09-04 16:08:01","open":0.925,"high":0.94,"low":0.9,"amount":280290,"amplitude":0.043956,"askPrice":0.93,"askSize":7000,"bidPrice":0.925,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-0.28145680854700855,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1626105600000,"exchange":"SEHK","adjPreClose":0.91,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.35410103842243507,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02137","defaultTab":"news","newsList":[{"id":"1154457483","title":"腾盛博药-B更新2026年8月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1154457483","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154457483?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:50","pubTimestamp":1788511833,"startTime":"0","endTime":"0","summary":"腾盛博药-B于2026年9月4日公布截至2026年8月31日的股份变动月报表。公告显示，公司法定/注册股本合计维持在1,200,000,000股普通股，面值为每股USD 0.000005，总额USD 6,000，与上月末保持一致。月报显示，截至7月底，公司已发行股份为721,978,947股，期末增加55,793股至722,034,740股；库存股份由12,723,500股增至12,923,500股，总股本由734,702,447股增至734,958,240股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663061720","title":"腾盛博药-B(02137.HK)8月31日斥资1.82万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663061720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663061720?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:33","pubTimestamp":1788183206,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02137","BK1587","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176753745","title":"腾盛博药-B回购2万股股份，涉资约1.82万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176753745","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176753745?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:28","pubTimestamp":1788182882,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年8月31日发布公告，披露当日公司在香港联交所进行股份回购。此次回购股份数量为20,000股，占该公司回购前已发行股本约0.0028%。本次回购价格每股介乎0.905港元至0.91港元之间，成交量加权平均价为0.9095港元，总耗资18,190港元。回购完成后，公司已发行股份总数保持在734,958,240股，其中包括722,034,740股在外流通股份及12,923,500股库藏股份。公司确认已遵守香港联交所上市规则及相关法律法规。本公告由联合公司秘书李安康博士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"腾盛博药-B回购2万股股份，涉资约1.82万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077159","title":"李安康减持腾盛博药-B(02137.HK)1500股 每股作价0.955港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663077159?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:10","pubTimestamp":1788174625,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02137","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125209203","title":"腾盛博药-B回购12万股股份，耗资约12.09万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125209203","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125209203?lang=zh_cn&edition=full","pubTime":"2026-08-25 20:07","pubTimestamp":1787659655,"startTime":"0","endTime":"0","summary":"2026年8月25日，腾盛博药生物科技有限公司公告，当日于香港联交所场内回购普通股12万股，约占回购前已发行股本的0.0166%。本次回购价格区间为每股0.995港元至1.03港元，合计支付约120,937.50港元，折合约12.09万港元。回购完成后，公司已发行股本由原有的722,174,740股减少至722,054,740股；同时，库藏股增至12,903,500股。腾盛博药-B于2026年6月16日通过购回授权，可回购股份总数为72,185,205股，截至目前累计已回购180,000股，占授权决议获通过当日已发行股份数目的约0.0249%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"腾盛博药-B回购12万股股份，耗资约12.09万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661272579","title":"腾盛博药-B(02137)8月24日斥资6.03万港元回购6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661272579","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661272579?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:32","pubTimestamp":1787581951,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B(02137)发布公告，于2026年8月24日，该公司斥资6.03万港元回购6万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02137","BK1587","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110406870","title":"腾盛博药-B于8月24日回购6万股并增发25.58万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1110406870","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110406870?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:21","pubTimestamp":1787581315,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年8月24日公布翌日披露报表，宣布通过行使多项股份计划向员工发行新股，并在香港联交所场内回购部分股份，导致公司已发行股份总数和库藏股数量同时变动。此外，公司于2026年8月24日通过香港联交所场内回购60,000股普通股，占变动前已发行股本约0.0083%，每股回购价范围介乎0.995港元至1.01港元，合计耗资约6.03万港元。上述发行及回购完成后，公司已发行股本增至722,174,740股，库藏股数量增至12,783,500股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"腾盛博药-B于8月24日回购6万股并增发25.58万股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661685251","title":"港股异动 | 腾盛博药-B(02137)涨超8% 中期公司拥有人应占亏损同比收窄32.08% 取得额外积极临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2661685251","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661685251?lang=zh_cn&edition=full","pubTime":"2026-08-21 11:33","pubTimestamp":1787283188,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，腾盛博药-B午前涨超8%，截至发稿，涨8.16%，报1.06港元，成交额5236.89万港元。消息面上，8月21日，腾盛博药-B发布截至2026年6月30日止6个月中期业绩，其他收入1950万元，同比减少30.6%；研发开支9830万元，同比减少16.0%；期内亏损1.01亿元，同比减少32.1%；公司拥有人应占亏损1.01亿元，同比收窄32.08%。于7月3日，公司亦公布其2b期ENRICH及 ENHANCE研究的治疗结束顶线数据。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","KCAI","BK1574","VXUS","BK4585","BK4588","02137","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661025810","title":"腾盛博药-B(02137.HK)：中期亏损为1.01亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661025810","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661025810?lang=zh_cn&edition=full","pubTime":"2026-08-21 07:27","pubTimestamp":1787268422,"startTime":"0","endTime":"0","summary":"格隆汇8月21日丨腾盛博药-B公布中期业绩，截至2026年6月30日止六个月，其他收入为人民币1950万元，同比减少30.6%。这主要是由于定期存款利率下降导致银行利息收入减少人民币790万元。期内亏损为人民币1.01亿元，与2025年同期的人民币1.49亿元相比，减少人民币4780万元或32.1%。亏损减少主要归因于其他收益增加以及运营开支减少。于7月3日，公司亦公布其2b期ENRICH及ENHANCE研究的治疗结束顶线数据。ENRICH及ENHANCE研究的详细数据预计将于2026年下半年公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260821/32341931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","02137","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661258620","title":"腾盛博药-B(02137.HK)发布中期业绩 公司拥有人应占亏损1.01亿元 同比收窄32.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661258620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661258620?lang=zh_cn&edition=full","pubTime":"2026-08-21 07:13","pubTimestamp":1787267616,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1587","BK1161","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195410958","title":"腾盛博药-B（02137）发布2026年中期业绩：期内亏损收窄至1.01亿元 研发及行政费用双降","url":"https://stock-news.laohu8.com/highlight/detail?id=1195410958","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195410958?lang=zh_cn&edition=full","pubTime":"2026-08-21 07:10","pubTimestamp":1787267450,"startTime":"0","endTime":"0","summary":"2026年8月21日，腾盛博药生物科技有限公司公布截至2026年6月30日止六个月未经审计的中期业绩。主要财务及业务数据如下：。期末银行存款及现金等价物合计17.71亿元，较2025年12月31日的19.41亿元减少1.70亿元，降幅8.8%，主要由于研发及日常营运支出所致。研发开支98.3百万元，同比减少18.7百万元，降幅16.0%，原因包括组织架构优化、薪酬框架调整及HBV项目2期研究活动逐步结束。财务成本0.132百万元，较上年同期1.9百万元下降。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661253668","title":"腾盛博药发布最新公司业务进展及2026中期业绩报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2661253668","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661253668?lang=zh_cn&edition=full","pubTime":"2026-08-21 07:10","pubTimestamp":1787267400,"startTime":"0","endTime":"0","summary":"ENRICH和ENHANCE研究的详细数据预计将于2026年下半年公布。腾盛博药董事长兼首席执行官洪志博士表示：\"2026年上半年，公司在HBV后期管线和早期研发能力建设方面均取得了重要进展。\" 公司业务及临床进展 HBV 项目 腾盛博药持续推进其HBV管线，重点通过创新的联合治疗方案实现更高的功能性治愈率。截至目前，ENSURE、ENRICH和ENHANCE研究中均未发现新的安全性问题。本公司正与服务提供商协作，以确定可能受影响的样本，并安排使用未受影响的检测试剂盒进行复检","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5030554_ZH30554_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5030554_ZH30554_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["02137","BK1587","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657421336","title":"腾盛博药-B(02137.HK)拟8月20日举行董事会会议审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2657421336","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657421336?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:57","pubTimestamp":1786114621,"startTime":"0","endTime":"0","summary":"格隆汇8月7日丨腾盛博药-B(02137.HK)宣布，董事会会议将于2026年8月20日(星期四)举行，藉以(其中包括)审阅及批准发布公司及其附属公司截至2026年6月30日止六个月的未经审核之中期业绩及其刊发，以及处理其他事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260807/32329146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1587","02137","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168397104","title":"腾盛博药-B（02137）将于2026年8月20日审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1168397104","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168397104?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:30","pubTimestamp":1786113058,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司（02137）8月7日公告称，公司董事会已定于2026年8月20日（星期四）召开会议，主要议程包括：\n\n1. 審閱及批准发布公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩；  \n2. 处理其他相关事项。\n\n公告显示，董事会目前由执行董事Zhi Hong博士及李安康博士，独立非执行董事Martin J Murphy Jr博士、Grace Hui Tang女士、徐耀华先生、Gregg Huber Alton先生及杨台莹博士组成。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169508528","title":"腾盛博药-B更新7月股份变动月报表，当月增发125,390股","url":"https://stock-news.laohu8.com/highlight/detail?id=1169508528","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169508528?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:37","pubTimestamp":1786005468,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年8月6日披露截至2026年7月31日止月份的证券变动月报表。报告显示，公司注册股本及法定股本均保持不变，注册股本数量为1,200,000,000股普通股，每股面值0.000005美元，合计6,000美元。7月内新增发行125,390股，无库存股数量变动。同时，公司于7月期间注销了1,235份受限制股份单位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137","09688","159992","02269","06606","01801","02359","09606","03347","06978","IBBQ","MEDX","03759","09966","00241","06618","06622","BK1574","01672","09995","BK1161","06996","02268"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1119741889","title":"腾盛博药6月股份变动月报表：当月总股本增至734,577,057股","url":"https://stock-news.laohu8.com/highlight/detail?id=1119741889","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119741889?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:08","pubTimestamp":1783415310,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年7月7日发布了截至2026年6月30日的股份变动月报表。报告期内，公司注册股本未发生变化，仍为1,200,000,000股，票面价值每股0.000005美元，合计注册股本为6,000美元。本月公司通过股权激励及股份奖励计划共计新增发行46,559股。报告期内未出现股份回购或注销情况。公司在公告中表示，已根据相关法律法规及香港联合交易所有限公司《上市规则》履行全部必要程序，并确认截至报告期末公司已维持足够的公众持股量。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197897139","title":"腾盛博药公布慢性乙肝治疗2b期Enrich和Enhance研究治疗结束顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1197897139","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197897139?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:04","pubTimestamp":1783037096,"startTime":"0","endTime":"0","summary":"腾盛博药（BRII-B）宣布了其针对慢性乙型肝炎治疗的2b期Enrich和Enhance研究在治疗结束时的顶线数据结果。该数据揭示了相关治疗方案在关键研究节点上的初步表现，为公司后续的临床开发决策提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137","BK1587","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648112639","title":"腾盛博药-B(02137)公布用于慢性乙型肝炎治疗的2b期ENRICH及ENHANCE研究的治疗结束时顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2648112639","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648112639?lang=zh_cn&edition=full","pubTime":"2026-07-03 07:04","pubTimestamp":1783033451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B 发布公告，本公司正在进行的2b期ENRICH及ENHANCE研究的治疗结束时结果。ENRICH及ENHANCE为两项2b期研究，旨在进一步明确BRII-179在慢性HBV治疗中的作用，并筛选后续开发的最佳联合治疗方案。ENRICH研究评估在elebsiran 及PEG-IFNα治疗前给予BRII-179作为免疫激活治疗的效果。HBsAg清除是评估功能性治愈方案的重要终点，但仍需通过停药随访确认其反弹情况及疗效持久性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02137","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644330744","title":"腾盛博药-B(02137)拟回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2644330744","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644330744?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:05","pubTimestamp":1781705109,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B 发布公告，董事有意根据股东于2026年6月16日通过的决议案授予董事的一般授权行使其权力，以购回不超过于2026年6月16日的已发行股份总数10%的公司股份。就公司根据购回授权购回的股份而言，公司可注销有关股份及╱或将其持作库存股份，视进行购回相关时间的市况及公司的资本管理需求而定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02137","BK1161","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.briibio.com","stockEarnings":[{"period":"1week","weight":-0.0312},{"period":"1month","weight":0},{"period":"3month","weight":-0.1545},{"period":"6month","weight":-0.3261},{"period":"1year","weight":-0.5231},{"period":"ytd","weight":-0.3404}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"腾盛博药生物科技有限公司是一家主要从事感染性疾病以及中枢神经系统疾病治疗方法开发的生物科技公司。该公司研发的产品主要包括乙型肝炎病（HBV）免疫治疗候选药物BRII-179、靶向乙型肝炎表面抗原（HBsAg）的研究性HBV中和单克隆抗体Tobevibart、以及用于治疗多重耐药性（MDR）和广泛耐药性（XDR）的革兰氏阴性菌感染的合成脂肽soralimixin（BRII-693）等。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.040695},{"month":2,"riseRate":0.6,"avgChangeRate":0.049398},{"month":3,"riseRate":0.2,"avgChangeRate":-0.163076},{"month":4,"riseRate":0.2,"avgChangeRate":-0.015797},{"month":5,"riseRate":0,"avgChangeRate":-0.081235},{"month":6,"riseRate":0.2,"avgChangeRate":-0.107834},{"month":7,"riseRate":0.8,"avgChangeRate":0.07356},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.000001},{"month":9,"riseRate":0.666667,"avgChangeRate":0.00052},{"month":10,"riseRate":0.2,"avgChangeRate":-0.127852},{"month":11,"riseRate":0.6,"avgChangeRate":0.286305},{"month":12,"riseRate":0.2,"avgChangeRate":-0.154392}],"exchange":"SEHK","name":"腾盛博药-B","nameEN":"BRII-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供腾盛博药-B(02137)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"腾盛博药-B,02137,腾盛博药-B股票,腾盛博药-B股票老虎,腾盛博药-B股票老虎国际,腾盛博药-B行情,腾盛博药-B股票行情,腾盛博药-B股价,腾盛博药-B股市,腾盛博药-B股票价格,腾盛博药-B股票交易,腾盛博药-B股票购买,腾盛博药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供腾盛博药-B(02137)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}